Rationale of concurrent Docetaxel Chemotherapy and radiation to chest wall & peripheral lymphatics after four cycles of AC chemotherapy in patients with early Breast Cancer
Keywords:Taxoids. Breast Cancer. Paclitaxel. Clinical Protocols. Antineoplastic Combined Chemotherapy Protocols. Neoadjuvant Therapy. Chest Wall. Cyclophosphamide. Doxorubicin.
The Cancer Research Group Pakistan has started this phase II study with the objectives to assess the feasibility of this regimen. Recently, docetaxel has emerged as the most powerful cytotoxic drug against breast cancer. As a single agent in second line treatment in phase II trials in metastatic breast cancer, it has achieved a response rate of 53-58% at a dose of 100 mg/m2 given every three weeks.
How to Cite
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments email@example.com